FindTrial
Sign In

Evaluating the effectiveness of one oral dose versus two oral doses of ivermectin in mass drug administration against scabies and tungiasis in Gamo zone, Southwest Ethiopia: a cluster randomized controlled trial

Evaluating the effectiveness of one oral dose versus two oral doses of ivermectin in mass drug administration against scabies and tungiasis in Gamo zone, Southwest Ethiopia: a cluster randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
PACTR
Registry ID
PACTR202401655267670
Enrollment
3782
Registered
2024-01-15
Start date
2023-11-25
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Two doses of ivermectin based MDA
one dose of oral ivermectin MDA

Sponsors

Arba Minch University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All participants who are older than two years in the selected clusters are eligible to participate in the study.

Exclusion criteria

Exclusion criteria: Those individuals with an allergy to Ivermectin, treatment within the last 7 days with Ivermectin, pregnant women, breastfeeding women, and participants who decline treatment will be excluded.

Design outcomes

Primary

MeasureTime frame
The prevalence of scabies—

Secondary

MeasureTime frame
? The prevalence of tungiaisis ? The prevalence of impetigo ? The proportion of adverse events associated with oral ivermectin MDA within 14 days of intervention—

Countries

Ethiopia

Contacts

Public ContactTsegaye Yohanes

Director for the Collaborative Research and Training Center for Neglected Tropical Diseases of Arba Minch University

tsegaye.yohanes@yahoo.com+251910083945

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026